Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Patients with treatment-resistant depression are costing Medicare big
A patient with treatment-resistant depression (TRD) costs Medicare 21%, or $8,000, more annually than a patient with depression that is controlled. | The report found that treatment-resistant depression patients cost Medicare about $46,000 annually, with the majority of costs attributed to hospitalizations and prescription costs.
TL;DRAI
TRD patients cost Medicare 21% more ($8,000/year); 1/3 of depressed Americans affected, $29-48B annual burden. Market scale signals opportunity for AI diagnosis and digital therapeutics to optimize treatment and reduce hospitalizations.
638 words~3 min read
